• December 6 , 2019

    8 Biopharma Trends to Watch in 2020

    According to the article “8 Biopharma Trends to Watch in 2020” published by Alex Philippidis on GEN(Genetic Engineering & Biotechnology News), there are eight biopharma-related trends in the coming new year. Presidential election, mergers and acquisitions, gene therapy CDMOs, Alzheimer’s disease, venture capital deals, CRISPR legal wrangle, genome editing ad
    Read more
  • December 1 , 2019

    2019 report advancing health through innovation

    Happy New Year! The beginning of a new year is always a rewarding time for the many dedicated staff at the FDA's Center for Drug Evaluation and Research (CDER) who work on approving new drug therapies. We look back over the past year and see how the work we did came together to help patients in need — one of the main reasons why many of us, including me, hav
    Read more
  • June 13 , 2019

    Following CAR-T pioneer¬s' footsteps, Tessa launches China JV in $120M deal

    These days just about every biotech serious about global development — and not just commercialization — has a Chi-na strategy. Tessa Therapeutics, a Baylor associated outfit based out of Singapore, is no exception.
    Read more
  • January 28 , 2019

    Zai Lab nabs speedy China regulatory review for PARP drug Zejula

    Chinese regulatory officials are signaling that they’re ready to whisk Zejula through the regulatory process.
    Read more
  • January 3 , 2019

    2019 M&A starts with a bang as BMS and Celgene agree $74bn merger

    The pairing will create a company with annual sales north of $34 billion, behind Pfizer, Novartis and Roche in terms of 2017 prescription drug sales and ahead of Merck & Co and Johnson & Johnson. There’s also plenty of scope for cost-cutting – the two companies think they can find $2.5 billion in “synergies” by 2022.
    Read more
  • October 1 , 2018

    Three Emerging Positive Trends to Watch in China Opening Up Huge Long-term Market Opportunity

    Three positive developments in China have evolved recently that could benefit the development, regulatory, reimbursement and - perhaps just as importantly-investment framework for biopharma. While still early, the Chinese govt is shifting from a network mostly "closed" to US Biopharma towards a more "open" and pro-innovation stance for medicine that could th
    Read more
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
If you would like to get in touch with us, please click here. Contact us